

IMMUTRAIN SECOND WORKSHOP IN COPENHAGEN



CLINICAL ONCOLOGY AND COMBINATION TREATMENT

DRAFT PROGRAM

Place: Panum Institute, University of Copenhagen – Room 13.1.83

Monday, October 2nd, 2017

PART I

13.00	Introduction to Tumor Biology based on the concepts of the Hallmarks of Cancer Niels Behrendt (BRIC), Section head, D.Sc., The Finsen Laboratory, Rigshospitalet / BRIC, University of Copenhagen niels.behrendt@finsenlab.dk
14.00	Introduction to oncogenes and tumor suppressor genes Mikkel Rohde , PhD., Cell Death and Metabolism, The Danish Cancer Society, Denmark mr@CANCER.DK
15.00	Coffee and cake
15.15	Cancer invasion - Basic principles and options for targeting Niels Behrendt (BRIC), Section head, D.Sc., The Finsen Laboratory, Rigshospitalet / BRIC, University of Copenhagen niels.behrendt@finsenlab.dk
16.15	Cancer epigenetics - and modulation of the immune system by epigenetic therapy in cancer treatment Kirsten Grønbæk , Prof. Department of Hematology, Rigshospitalet kisserg6@gmail.com
17.15	End of day one

Organised by Capital regionh of Copenhagen/Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Funded by the Innovative Training Network IMMUTRAIN project of the European Union's Horizon 2020 research and innovation programme, Marie Skłodowska-Curie grant agreement N°641549



Herlev og Gentofte Hospital



OBS! Place: University Hospital Herlev, Herlev Ringvej 75, 2730 Herlev – Room 53 K2D

Tuesday, October 3rd, 2017

PART II

- 09.00 Conventional therapy overview
Morten Nielsen, MD., CCIT, University Hospital Herlev
morten.nielsen.03@regionh.dk
- 09.45 Chemotherapy
Lisa Sengeløv, Prof., Dept. Head, Dept of Oncology, University Hospital Herlev
Lisa.Sengeloev@regionh.dk
- 10.30 Coffee
- 10.45 Pathology/diagnostics
Peter Nørgaard, MD PhD, Consultant in Pathology, Dept. of Pathology, University Hospital Herlev,
pehno@regionh.dk
- 11.30 Tyrosine kinase inhibitors
Anne Kirstine Hundahl, Phd, Department of oncology, University Hospital Herlev
Anne.Kirstine.Hundahl.Moeller@regionh.dk
- 12.15 Lunch

PART III

- 13.00 Prostate cancer
Per Kongsted, MD, PhD., Dept Oncology, University Hospital Herlev, DK
Per.Kongsted@regionh.dk
- 13.45 Bladder cancer
Lisa Sengeløv, Prof., Dept. Head, Dept of Oncology, University Hospital Herlev, DK
Lisa.Sengeloev@regionh.dk
- 14.30 Coffee
- 15.00 Colorectal cancer
Julia Johansen, Prof., dr. med., Dept Oncology, University Hospital Herlev), DK
Julia.Sidenius.Johansen@regionh.dk
- 15.45-17.00 Hematological malignancies; conventional treatments
Lene Knudsen, Dept. Head, Dept of Hematology, University Hospital Herlev, DK.
lene.meldgaard.knudsen@regionh.dk

Organised by Capital regionh of Copenhagen/Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Funded by the Innovative Training Network IMMUTRAIN project of the European Union's Horizon 2020 research and innovation programme, Marie Skłodowska-Curie grant agreement N°641549



Herlev og Gentofte
Hospital



OBS! Place: Panum Institute, University of Copenhagen – Holst Auditorium

Wednesday, October 4th, 2017

PART IV

09.15	Radiotherapy Maja Maraldo , MD, PhD., Radiation therapy, Department of Clinical Oncology, Section of Radiotherapy, State University Hospital Maja.Vestmoe.Maraldo@regionh.dk
10.00	PET/CT in diagnosis and monitoring Helle Westergren Hendel , PhD., Dept of Clinical Physiology and Nuclear Medicine, University Hospital Herlev Helle.Westergren.Hendel@regionh.dk
10.45	Coffee
11.00	Utilization of public repositories for investigative studies and biomarker validation Graham Ball , PhD, John van Geest Cancer Research Centre, Nottingham Trent University graham.ball@ntu.ac.uk
11.45	Commercialization of science Bjarke Poulsen , University of Copenhagen bjarke.poulsen@adm.ku.dk
12.30	Combining conventional therapies with immunotherapy Troels Holz Borch , MD, CCIT troels.holz.borch@regionh.dk
13.15- 14.00	ESR meeting, voting of new ESR representative

Organised by Capital regionh of Copenhagen/Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev,
Funded by the Innovative Training Network IMMUTRAIN project of the European Union's Horizon 2020 research and innovation
programme, Marie Skłodowska-Curie grant agreement N° 641549



Herlev og Gentofte
Hospital

